Fig 1: A truncated isoform of GPSM2 promotes CD4+ T-cell migration in SLE. (A) Representative example of western blot analysis of GPSM2 and the truncated 35 kDa GPSM2 isoform in CD4+ T cells from patients with SLE (SLE) and HCs. GPSM2 overexpressing lysate served as a positive ctrl (+); no protein served as a negative ctrl (-). (B) Comparison of GPSM2 expression in CD4+ cells from patients with SLE (n=10) and healthy individuals (n=9). (C) Expression of the truncated GPSM2 isoform in CD4+ cells from patients with SLE (n=10) and healthy individuals (n=9). (D) Schematic view of the experimental set-up of an in vitro T-cell migration assay. (E) Inhibition of the truncated GPSM2 isoform with blocking antibodies (block) or ctrl antibodies leads to decreased migration of CD4+ T cells from patients with SLE (n=9). Data are presented as mean±SEM. Significance was calculated using unpaired (B, C) or paired (E) Student’s t-test. ctrl, control; GPSM2, G-protein signalling modulator 2; HC, healthy control; n.s., not significant.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for GPSM2 Overexpression Lysate